MicroRNA-216b靶向DCLK1调控卵巢癌HO-8910细胞的增殖迁移和侵袭

doi:10.3969/j.issn.1006-6233.2021.04.02

摘要
图/表
参考文献
相关文章 (12)

全文: PDF (1635 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨MicroRNA-216b(miR-216b)对卵巢癌HO-8910细胞增殖、迁移和侵袭的影响。方法: 收集30例卵巢癌患者癌组织和癌旁组织,采用qPCR检测癌组织和癌旁组织miR-216b的表达。采用HO-8910细胞为对照组,转染空载质粒HO-8910细胞为阴性对照组,转染miR-216b mimic的HO-8910细胞为过表达组,转染miR-216b inhibitor HO-8910细胞为低表达组。采用CCK8法、划痕实验、平板克隆、Transwell检测各组细胞增殖、迁移和侵袭能力,采用Western blot和qPCR检测各组细胞双皮质素样激酶1( Doublecortinlike kinase 1,DCLK1)蛋白和mRNA的表达情况。结果: 卵巢癌患者癌组织中miR-216b的表达量明显低于癌旁组织(P<0.05); CCK8法、划痕实验、Transwell结果显示,相对于对照组和阴性对照组,miR-216b mimic组细胞增殖、迁移和侵袭能力显著降低(P<0.05),miR-216b inhibitor组显著增加(P<0.05);Western和qPCR结果显示,与对照组和阴性对照组,miR-216b mimic组细胞DCLK1蛋白和mRNA表达水平显著降低(P<0.05),miR-216b inhibitor组显著增加(P<0.05)。结论: miR-216b具有靶向DCLK1,进而抑制卵巢癌HO-8910细胞增殖、迁移和侵袭的作用。miR-216b可能卵巢癌诊断治疗的新靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	樊涛
	李江鹏

关键词 ： miR-216b, 双皮质素样激酶1, 卵巢癌HO-8910细胞, 增殖

Abstract：Objective: To investigate the effect of MicroRNA-216b (miR-216b) on the proliferation, migration and invasion of ovarian cancer HO-8910 cells.Methods: The expression of miR-216b in cancer and paracancerous tissues of 30 patients with ovarian cancer was detected by qPCR. Experimental cells were divided into four groups: control group (normal HO-8910 cells), negative control group (transfected empty plasmid HO-8910 cells), overexpression group (transfected miR-216bmimicHO-8910 cells), low expression group (transfected miR-216binhibitorHO-8910 cells). CCK8 assay, scratch test, plate cloning and Transwell were used to detect the ability of cell proliferation, migration and invasion. Westernblot and qPCR were used to detect the expression of biscorticoid kinase 1 (Doublecortinlikekinase1, DCLK1) protein and mRNA. Results: The expression of miR-216b in ovarian cancer tissues was significantly lower than that in paracancerous tissues, and the results of CCK8 assay, scratch test and Transwell showed that the ability of cell proliferation, migration and invasion in miR-216bmimic group was significantly lower than that in control group and negative control group, while that in miR-216binhibitor group was significantly higher than that in control group and negative control group. The results of Western and qPCR showed that the expression levels of DCLK1 protein and mRNA in miR-216bmimic group were significantly lower than those in control group and negative control group, while those in miR-216binhibitor group were significantly higher than those in control group and negative control group. Conclusion: MiR-216b can target DCLK1 to inhibit the proliferation, migration and invasion of ovarian cancer HO-8910 cells. MiR-216b may be a new target for diagnosis and treatment of ovarian cancer.

Key words： miR-216b Dicorticoid kinase 1 Ovarian cancer HO-8910 cells Proliferation

基金资助:陕西省医学科学研究重点课题计划,(编号:2016JM1214)

通讯作者: 李江鹏

引用本文:

樊涛, 李江鹏. MicroRNA-216b靶向DCLK1调控卵巢癌HO-8910细胞的增殖迁移和侵袭[J]. 河北医学, 2021, 27(4): 534-538.
FAN Tao, LI Jiangpeng. MicroRNA-216b Targets DCLK1 Regulating the Proliferation, Migration and Invasion of Ovarian Cancer HO-8910 Cells. HeBei Med, 2021, 27(4): 534-538.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.04.02 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I4/534

[1] 陈健.RIP1蛋白在卵巢癌中的表达及其对卵巢癌细胞增殖和化疗敏感性的影响[J].现代肿瘤医学,2020,28(16):2770~2774.
[2] Caihua D,Fu QY,Dan Z,et al.NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer[J].Journal of Cellular Biochemistry,2020,121(11):4470~4483.
[3] Alyssa A.H,Demetra H.H,Whitney H,et al.Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer[J].BMC Cancer,2020,20(1):284~296.
[4] Mayuko M,Kenjiro S,Koji Na,et al.Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells[J].Scientific Reports,2020,10(1):7~30.
[5] Shu YR,Peirong L,Jingrong W,et al.Guanhua Du.Circular RNAs: promising molecular biomarkers of human aging-related diseases via functioning as an miRNA sponge[J].Molecular Therapy - Methods & Clinical Development,2020,18(2):215~229.
[6] Grunt TW,Slany A,Semkova M,et al.Membrane disruption,but not metabolic rewiring,is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.[J].Scientific Reports,2020,10(1):14877~14877.
[7] Zhao HW,Hayat H,Ma XH,et al.Moore Anna.Molecular imaging and deep learning analysis of uMUC1 expression in response to chemotherapy in an orthotopic model of ovarian cancer.[J].Scientific reports,2020,10(1):4942~14942.
[8] Chiman M,Rezvan N.DCLK1 as a promising marker for radioresistance in colorectal cancer[J].Journal of Gastrointestinal Cancer,2020,51(4) :714~715.
[9] Lian QZ,Sheng LZ,Ertao G,et al.DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling[J].Pflügers Archiv - European Journal of Physiology,2020,472(8):1041~1049.
[10] Jingfu L,Zhen L,Wen HT,et al.Identification of downregulated circRNAs from tissue and plasma of patients with gastric cancer and construction of a circRNA-miRNA-mRNA network.[J].Journal of Cellular Biochemistry,2020,121(11):4590~4600.
[11] Shahjaman,Manir HM,Rezanur R,et al.Robust identification of differentially expressed genes from RNA-seq data[J].Genomics,2020,112(2):2000~2010.